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One of the major projects of the Worldwide Network for Blood and Marrow Transplantation (WBMT) is to
promote hematopoietic stem cell transplantation (HSCT) in emerging countries in the world. For these
countries, HLA haploidentical HSCT (haplo-HSCT) from family members is an attractive approach because of
its cost effectiveness. To learn the current status, including recent trends, of haplo-HSCT, the WBMT invited
speakers frommajor transplant centers in 3 regions (Asia, Europe, and North America) to present at its annual
WBMT Joint Session. This article represents the direct reports from these 3 speakers in addition to in-
troductions by 2 WBMT speakers who address data from the Global Transplant Activity survey. It must be
emphasized, however, that certain promising results of haplo-HSCT presented in this article were obtained at
well-experienced institutes.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION presented in this article were the result of studies conducted
One of the major projects of the Worldwide Network for
Blood and Marrow Transplantation (WBMT) is to promote
hematopoietic stem cell transplantation (HSCT) in emerging
and developing nations. For these countries, HLA
haploidentical HSCT (haplo-HSCT) from family members is
an attractive approach because of its cost effectiveness. To
understand the current status and the future trends of haplo-
HSCT, the WBMT/Tandem Joint Session invited experts from
major transplant centers in 3 regions, Asia, Europe, and
North America. This article is the synthesis of reports from
these individuals. It must be emphasized, however, that the
optimism surrounding the outcomes of haplo-HSCTdgments on page 26.
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ty for Blood and Marrow Transplantation.and analyzed at institutes with signiﬁcant experience in the
ﬁeld.
Allogeneic HSCT (allo-HSCT) is a potentially curative
treatment of a wide variety of malignant and nonmalignant
disorders of hematopoiesis. Since the ﬁrst HSCT in the late
1950s, more than 1 million procedures have been completed
worldwide, and the annual transplant rate is now close to
70,000 per annum without any evidence of a plateau. Of
these, approximately 45% are allogeneic, and major in-
dications include leukemia (82%), lymphomas (11%), and
bone marrow failure (6%).
Historically, the best outcomes of allo-HSCT have been
obtained when the donor is an HLA-matched sibling [1].
Unfortunately, each sibling of a patient has only a 25% chance
of being HLA-matched, and with the small family sizes seen
in the many nations, patients have only about a 30% chance
of having an HLA-matched sibling donor.With the expansion
of the unrelated donor pool to now more than 26 million
donors worldwide, the numbers of unrelated allo-HSCTs
have increased to 16,000 per year. The results of allo-HSCT
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dramatically over the last 25 years, and the overall and
event-free survival rates aftermatched unrelated donor stem
cell transplantation (HSCT) rival those seen after HLA-
matched sibling transplantation. Nevertheless, well-
matched donors cannot be found for many patients, and
many other patients either relapse or become too ill while
waiting for a donor to be identiﬁed.
Patients lacking an HLA-matched sibling or unrelated
donor have 3 different options for graft sources: partially
HLA-mismatched unrelated adult donors, unrelated donor
umbilical cord blood [2], and partially HLA-mismatched or
HLA-haploidentical, related donors [3,4]. An HLA-
haploidentical donor is a related donor who shares exactly
1 HLA haplotype and differs by a variable number of HLA
genes on the unshared haplotype. Mendelian genetics
dictate that each biological parent and each biological child
of a patient is HLA-haploidentical; each sibling, half-sibling,
aunt, or uncle has a 50% likelihood of being HLA-
haploidentical; and each cousin, niece, or nephew has a
25% chance of being HLA-haploidentical. Herein lies the
greatest advantage of the haploidentical donor option: A
haploidentical donor can be found for nearly every patient
that is referred for allo-HSCT. Further, graft acquisition costs
are modest compared with unrelated donor options, and the
donor is readily available to donate more stem cells or lym-
phocytes in the event of graft failure or relapse, respectively.
Historically, the major limitation of haplo-HSCT has been
intense, bidirectional alloreactivity resulting in unacceptably
high incidences of graft failure, graft-versus-host disease
(GVHD), and nonrelapse mortality and poor rates of overall
and event-free survival [5-7]. Beginning in the 1990s, the
picture for haplo-HSCT brightened with the development of
“megadose” T celledepleted haplo-HSCT by the group led by
Massimo Martelli Perugia, Italy [4]. Currently, 3 main ap-
proaches control GVHD after haplo-HSCT:
1. The megadose HSCT approach using peripheral blood
stem cell grafts positively selected for CD34þ cells,
depleted of CD3þ and CD19þ cells, or depleted of T cells
bearing the T cell receptor.
2. The GIAC protocol, pioneered in China, comprising
Granulocyte-colony-stimulating factor stimulation of
the donor; Intensiﬁed immunosuppression through
post-transplantation cyclosporine, mycophenolate
mofetil, and short-course methotrexate; Antithymo-
cyte globulin added to conditioning to help prevent
GVHD and aid engraftment; and Combination of pe-
ripheral blood stem cell and bone marrow allografts.
3. High-dose, post-transplantation cyclophosphamide
(PTCy).THE ASIAN EXPERIENCE
Haplo-HSCT is an important alternative transplant option
for most patients with hematological disease and is available
without search or acquisition costs to the patient. However,
the success of haplo-HSCT was previously hindered by high
incidences of GVHD and graft rejection. A number of studies
were undertaken to devise strategies to overcome the
immunological barrier, in which G-CSF (ﬁlgrastim) was
recognized as a novel mediator of T cell tolerance, by polar-
ization of T cells from Th 1 to Th 2 phenotype, regulatory
T cell/Th 17 balance toward regulatory T cells, andmodulation of non-T regulatory cells such as dendritic cells
and myeloid-derived suppressor cells, among others.
Over the past 15 years, by using a combination of
G-CSFemobilized bone marrow and peripheral blood cells,
as well as antithymocyte globulin administration for the
prophylaxis of GVHD and graft rejection, the Beijing group
initiated one of the earliest clinical trials to explore unma-
nipulated myeloablative haplo-HSCT for leukemia [8]. The
Beijing Protocol was shown to be a reliable treatment strat-
egy for patients without a suitable HLA-matched donor for
the following reasons: graft rejection was reduced with 99%
of patients achieving sustained myeloid engraftment and
92% platelet engraftment; the risk of lethal GVHD was not
increased when compared with HLA-matched allogeneic
HSCT (grades III to IV acute GVHD was 11% to 14% and
extensive chronic GVHD 19% to 23%); haplo-HSCT achieved
similar clinical efﬁcacy as allo-HSCT from an HLA-identical
sibling donor or matched unrelated donor and was found
to be superior to cord blood transplantation in the treatment
of children with hematological malignances and chemo-
therapy in treatment of intermediate/high-risk acute mye-
logenous and acute lymphoblastic leukemias in ﬁrst
complete remission; and the health-related quality of life
and the cumulative incidence of late effects was found to be
similar or even better for patients receiving haplo-HSCT
compared with allo-HSCT from identical sibling donor.
In recent years the Beijing Protocol has been improved in
many aspects and developed into an integrated haplo-HSCT
system. The indications for haplo-HSCT have been
extended from hematological malignancy to include
nonmalignant disease such as severe aplastic anemia and
inherited disorders. A series of new conditioning regimens
were introduced, including total body irradiationebased
regimens and other optimized regimens for certain groups of
patients. Selected older patients aged >50 years with low
hematopoietic cell transplantationespeciﬁc comorbidity in-
dex and good performance status have been shown to safely
undergo haplo-HSCT. Donor selection based on non-HLA
systems, such as donor-speciﬁc antibodies, KIR, and family
relationship, now play a predominant role in haplo-HSCT. It
has been suggested that choosing young, male, NIMA-
mismatched donors is a reasonable strategy, whereas
transplants from older multiparous women and NIPA-
mismatched donors should probably be avoided. Donor-
speciﬁc antibodies were indicated to be associated with
primary graft failure, transplant-related mortality, and infe-
rior overall survival after haplo-HSCT. Using a combination of
reliable biomarkers (minima; residual disease detection,
leukemia initiating cells, chimerism) and powerful inter-
vention strategies (donor lymphocyte infusion, IFN-,) using
pre- and post-transplant risk stratiﬁcation directed in-
terventions has reduced relapse risk after haplo-HSCT.
The Beijing Protocol has been widely incorporated into
clinical practice in China, including modiﬁed protocols such
as haplo-HSCT with G-CSFemobilized peripheral blood
instead of bone marrow plus peripheral blood and the use of
low-dose antithymocyte globulin; haplo-HSCT has become
the largest donor source compared with identical sibling
donor from 2013 and now is used in almost 48% of allo-HSCT
in China. Furthermore, cooperation between the major
transplant centers of China has enabled successful imple-
mentation of several multicentered studies for haplo-HSCT.
In other countries, modiﬁed haplo-HSCT protocols with
reduced-intensity conditioning have been carried out in
Japan and Korea, andmodiﬁed protocols with G-CSFeprimed
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Europe. It has been estimated that more than half of the HLA
haplotype mismatched transplantations performed world-
wide will follow the Beijing Protocol [9]. With the develop-
ment of international multicenter clinical trials between Asia
and the West along with advances in translational research,
haplo-HSCT may well become the dominant form of HSCT.
THE EUROPEAN EXPERIENCE
Allo-HSCT represents the only possible cure for adult
patients with high risk acute leukemia. In the absence of an
HLA-matched donor, haplo-HSCT is an attractive alternative
that provides the possibility of transplantation to almost all
patients needing an allo-HSCT. The numbers of haplo-HSCT
in Europe are constantly increasing, with a steep rise in
recent years reaching about 8% of all allo-HSCT in 2013. In
view of the slow immune reconstitution leading to a high
incidence of both life-threatening infections and relapse
after T celledepleted haplo-HSCT (unless regulatory T cells/
Tcon or other modes of post-transplant adoptive cellular
immunotherapies are given), currently most haplo-HSCTs in
Europe are performed with a T cellereplete approach.
However, many questions are still open, and most reports of
haplo-HSCTs are from single centers and with rather short
follow-up periods in a limited number of patients.
The Adult Leukemia Working Party of the European
Group for Blood andMarrow Transplantation took advantage
of large registry data and performed several retrospective
registry studies in the last few years, trying to address these
open issues in the ﬁeld. Speciﬁcally, T cellereplete haplo-
HSCTs were compared with cord blood transplantation in
acute leukemia to address the topic of alternative donor
transplants [10]. Similarly, in 2 separate studies,
T cellereplete haplo-HSCT has been compared with matched
and mismatched unrelated allo-HSCT (S. Piemontese, per-
sonal communication) and autologous transplantations for
patients with acute leukemia [11]. Theoretically, there was
the idea that the broad HLA disparity involved in haplo-HSCT
would result in a stronger graft-versus-leukemia effect in
comparison with HLA-matched transplants. This question
has been addressed in another study from the European
Group for Blood and Marrow Transplantation [12]. Other
studies have researched myeloablative versus reduced-
intensity conditioning for unmanipulated haplo-HSCT.
Finally, very recently the impact of HLA disparities on the
outcomes after haplo-HSCT in acute leukemia has been
examined.
THE U.S. EXPERIENCE
PTCy is a special case of the more general phenomenon of
drug-induced immunological tolerance, ﬁrst developed by
Schwartz and Dameshek [13]. In drug-induced immunolog-
ical tolerance, an animal is exposed to an antigen for the ﬁrst
time and shortly thereafter treated with a drug that is
selectively toxic to dividing cells. Because an immunogenic
antigen exposure induces the activation and proliferation of
antigen-speciﬁc B cells and T cells, a properly timed admin-
istration of the cytotoxic drug will selectively inactivate the
antigen-responsive lymphocytes while sparing lymphocytes
speciﬁc for other antigens. Berenbaum [14] found that
cyclophosphamide could prolong the survival of rat skin al-
lografts if the drug was administered approximately 1 to
3 days after graft placement.
In a series of pioneering experiments, Mayumi et al. [15]
found that complete tolerance to minor histocompatibilityantigens could be induced by infusing mice intravenously
with a high dose of spleen cells bearing these antigens fol-
lowed in 48 to 72 hours by intraperitoneal injection of a high
dose of cyclophosphamide. Luznik et al. [16] achieved toler-
ance and durable chimerismwithMHC-incompatible cells by
conditioning mice with ﬂudarabine and 200 cGy total body
irradiation, transplanting marrow on day 0, and giving high
dose cyclophosphamide on day 2. This basic regimen was
then translated to the clinic. Initial studies used a single dose
of cyclophosphamide 50 mg/kg i.v. on day 3, but subsequent
trials used this dose of drug on each of days 3 and 4 after
transplantation.
The regimen that has been used in over 500 patients at
Johns Hopkins in Baltimore consists of the following; Cy
14.5 mg/kg/day on days 6 and 5; ﬂudarabine 30 mg/m2/
day on days 6, 5, 4, 3, and 2; total body irradiation
200 cGy on day 1; Cy 50 mg/kg/day on days 3 and 4 fol-
lowed by G-CSF 5 mg/kg/day, mycophenolate mofetil 15 mg/
kg/day, and tacrolimus. The incidences of acute and chronic
GVHD were remarkably low, and nonrelapse mortality was
acceptable at 17% in the long term. Overall and event-free
survival rates at 5 years after transplantation were in the
range of 40% and 30%, respectively. When adjusted for dis-
ease risk index according to the methodology developed by
Armand [17], outcomes of reduced-intensity conditioning
and haploidentical bone marrow transplantation with PTCy
are roughly equivalent to the outcomes of patients receiving
grafts from HLA-matched donors. These results suggest that
high dose, post-transplant Cy substantially mitigates allor-
eactivity after haploidentical bone marrow transplantation,
to the point that outcomes are equivalent to those seenwhen
using HLA-matched donors.
Roughly equivalent outcomes of HLA-matched and hap-
loidentical bone marrow transplantation with PTCy have
been reported in single-center retrospective comparisons by
other groups [18-21]. More recently, a case-control study
from the Center for International Blood and Marrow Trans-
plant Research showed equivalent outcomes for acute
myeloid leukemia patients receiving either HLA-matched
unrelated donor stem cells or haploidentical bone marrow
with PTCy. High dose PTCy for GVHD prophylaxis has now
been used with good results after myeloablative [19] and
nonmyeloablative [18] conditioning and with ﬁlgrastim-
mobilized stem cells as well as with bone marrow as the
graft source [22].
Although haplo-HSCT with PTCy is now in widespread
use in the United States, as well as in France, Italy, Australia,
and elsewhere [18,21,23], this approach may ultimately have
its greatest impact in developing countries, where economic
resources are more limited. Unrelated donor registries and
cord blood banks are expensive to set up and maintain. In
contrast to haplo-HSCT strategies that require graft manip-
ulation, no special expertise or cell separation devices are
required. Many centers that have adopted the use of PTCy for
GVHD prophylaxis have achieved results comparable with
those obtained at Johns Hopkins, the center that pioneered
this approach. This result suggests no signiﬁcant “learning
curve” and that similar results can be expected as new cen-
ters adopt this strategy. Still, major questions about the PTCy
approach remain. How dose PTCy compare with megadose
stem cell transplantation or to the GIAC protocol for haplo-
HSCT? How does haplo-HSCT with PTCy compare with un-
related umbilical cord blood transplantation, to matched
unrelated donor HSCT, or to matched sibling HSCT? Can
haplo-HSCT with PTCy be extended on a large scale to treat
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anemia [25], immunodeﬁciency, or even autoimmune
disease? Can PTCy be used to induce hematopoietic chime-
rism and tolerance to solid organ transplants [26]? Many of
these questions are being actively investigated, and results
should be available within the next 5 years.
CONCLUSION
Haplo-HSCT is clearly increasing in activity and provides a
clear path to identifying a potential donor for an HSCT
recipient candidate where no other exists or is feasible
because of immunological or ﬁnancial factors, thus providing
the promise of a donor for almost every eligible patient. The
safe use of these donors in regions with newly developing
transplant programs will require careful mentoring by
centers and individuals experienced in allo-HSCT.
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